Accepted Manuscript

Synthesis, spectroscopic, crystal structure and *in vitro* cytotoxicity studies of *N*-thiophenoyl-*N*'-substituted phenyl thiocarbamide derivatives

Sunil K. Pandey, Seema Pratap, Gaetano Marverti, Manpreet Kaur, Jerry P. Jasinski

PII: S0022-2860(18)31432-7

DOI: https://doi.org/10.1016/j.molstruc.2018.12.011

Reference: MOLSTR 25948

To appear in: Journal of Molecular Structure

Received Date: 10 October 2018

Revised Date: 24 November 2018

Accepted Date: 4 December 2018

Please cite this article as: S.K. Pandey, S. Pratap, G. Marverti, M. Kaur, J.P. Jasinski, Synthesis, spectroscopic, crystal structure and *in vitro* cytotoxicity studies of *N*-thiophenoyl-*N*'-substituted phenyl thiocarbamide derivatives, *Journal of Molecular Structure* (2019), doi: https://doi.org/10.1016/j.molstruc.2018.12.011.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



Graphical Abstract

Synthesis, spectroscopic, crystal structure and *in vitro* cytotoxicity studies of N-thiophenoyl-N'-substituted phenyl thiocarbamide derivatives

Sunil K. Pandey ^a, Seema Pratap ^{a*}, Gaetano Marverti ^b, Manpreet Kaur ^c Jerry P. Jasinski ^c

^a Department of Chemistry (M.M.V), Banaras Hindu University, Varanasi–221005, UP, India

^b Department of Biomedical, Metabolic and Neural Sciences, University of

Modena and Reggio Emilia, 41125 Modena, Italy

^c Department of Chemistry, Keene State College, 229 Main Street, Keene, NH 03435-2001, USA.

In the present study, a series of biologically active N, N'–disubstituted thiocarbamide compounds (1–8) have been synthesized and characterized by some spectroscopic (FT-IR, ¹H and ¹³C NMR, UV-Visible) techniques. The molecular structure of compound 1 was determined by single crystal X-ray diffraction analysis. All the synthesized compounds (1–8) and five more (9–13) were screened for their *in vitro* cytotoxicity activities.



Synthesis, spectroscopic, crystal structure and *in vitro* cytotoxicity studies of N-thiophenoyl-N'-substituted phenyl thiocarbamide derivatives

Sunil K. Pandey ^a, Seema Pratap ^{a*}, Gaetano Marverti ^b, Manpreet Kaur,^c Jerry P. Jasinski ^c

^aDepartment of Chemistry (M.M.V), Banaras Hindu University, Varanasi–221005, UP, India ^bDepartment of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, 41125 Modena, Italy

^cDepartment of Chemistry, Keene State College, 229 Main Street, Keene, NH 03435-2001, USA.

Abstract

A series of eight biologically active N, N'-disubstituted thiocarbamide compounds (1-8) have been prepared from thiophene-2-carbonyl isothiocyanate and various substituted aromatic aniline, 4-chloro-3-nitrophenyl primary amines (2,4-dichlorophenyl aniline, 4methoxycarbonylphenyl aniline, 3-methoxycarbonylphenyl aniline, 2-methoxycarbonylphenyl aniline, 4-methoxyphenyl aniline, 2-methoxyphenyl aniline and 2-nitrophenyl aniline). Their structures were confirmed by elemental analyses, various spectroscopic techniques ((FT-IR, ¹H and ¹³C NMR) and single crystal X-ray analysis of compound (1). In the molecular structure of compound (1) twisted confirmation of the carbonyl and thiocarbonyl group across C-N bond of thiocarbamide moiety and an offset face-to-face π - π stacking between two thiophene and two benzene ring of two molecules is observed. In vitro cytotoxicity assay of all the above compounds and five more (9-13) were carried out using seven human cancer cell lines; cervical (2008 and C13*), colorectal (HT29 and HCT116) and ovarian carcinoma (A2780, A2780/CP and IGROV-1). The results revealed that compounds 1, 11, 12 and 13 displayed promising inhibitory activity against all the cell lines tested.

* Email: drseemapratap@gmail.com

Keywords: Thiocarbamide; X-ray crystal structure; *In vitro* Cytotoxicity; Spectroscopic techniques; π – π stacking.

1. Introduction

N, N'-disubstituted thiocarbamides represent one of the most useful class of compounds with a wide range of applications in medicinal, analytical and other fields [1–5]. The structural motif of these compounds [-C(O)NHC(S)NH-] is composed of nitrogen, oxygen and sulfur heteroatoms which facilitate their hydrogen bonding abilities with different molecules and multitude of coordination behaviour with a variety of heavy trantion metal ions[6–9]. The presence of thiocarbonyl moiety influences the lipophilicity/hydrophilicity and the electronic properties of the compounds [10, 11]. The medicinal applications of these compounds include their antibacterial, -fungal, anti-tubercular, anti-thyroid, anti-helmintic, rodenticidal, insecticidal, and herbicidal and plant growth regulator activities [12–17]. They also exhibit significant anticancer properties against various leukemia and solid tumors, however, the reports are very limited [18, 19]. Their inhibitory activity against protein tyrosine kinases (PTKs) [20, 21], human sirtuin type proteins, topoisomerase II and DNA repair synthesis has been reported [22].

These compounds have also been successfully used in liquid-liquid extraction of precious metals (Pt, Pd, Au Ag.), as anion and cation sensors [23, 24], liquid crystal materials [25, 26], as catalyst in chemical reactions [6, 27], as precursors or intermediates towards the synthesis of a variety of heterocyclic compounds. Due to non-linear optical properties single crystal of substituted thiocarbamides are being extensively employed in the electronic industry as polarization filters, electronic light shutters, electronic modulators, and as components in electrooptic and electro-acoustic devices, etc [28, 29].

We have reported anticancer properties of few N, N'-substituted thiocarbamide derivatives in our previous publications [12, 13, 30, 31]. Since, optimizing compound structure is a usual strategy to design and construct new antitumor agents, in the present study; we report the synthesis and anticancer activity of a series of novel thiophene containing substituted thiocarbamides.

2. Experimental Details

2.1. Chemicals, Instruments and Methods

Thiophene-2-carbonyl chloride, substituted aromatic primary amines (2, 4 - dichlorophenyl aniline, 4-chloro-3-nitrophenyl aniline, 4-methoxycarbonyl) phenyl aniline, 3-methoxycarbonyl phenyl aniline, 2-methoxycarbonyl phenyl aniline, 4-methoxyphenyl aniline, 2-methoxyphenyl aniline) and ammonium thiocyanate were purchased from Merck (Germany). Analytical grade acetone, acetonitrile, and dichloromethane were purchased from Rankem. The acetone was dried and freshly distilled prior to use. Melting points was measured on a X–4 digital melting-point apparatus and were uncorrected. Elemental analyses were performed on a CE-440 Exeter Analytical CHN analyzer. The infrared spectra of the title compounds as KBr pellets (4000–400 cm⁻¹) were recorded on a Varian 3100 FT-IR Excalibur series spectrophotometer.¹H and ¹³C NMR spectra were recorded in CDCl₃ by using TMS as an internal standard on a JEOL FT-NMR AL 500 spectrometer. The splitting of proton resonances in the reported ¹H NMR spectra were remarked as s = singlet, d = doublet, t = triplet, dd = doublet of doublets, and m = multiplet; coupling constants are reported in Hz. UV-Visible spectra were recorded on a Shimadzu (-UV-) 1700 Pharma Spec spectrophotometer, USA. A rectangular quartz cell with optical path length of 1cm was used.

2.2. Crystal structure determination

Data collection was performed using CrysAlisPRO on an Oxford Diffraction Xcaliber Ruby Gemini CCD differactometer using graphite- monochromatic CuKa (k = 1.54178 Å) at 123 K. The structure was solved by direct methods and refined by full-matrix least-square on F² using SHELXL-97 [32]. The non-hydrogen atoms were refined with anisotropic thermal parameters. All hydrogen atoms were geometrically fixed and allowed to refine using the riding model. The details of the single crystal X-ray data collection, structure solution and structure refinement parameters are given in **Table 1**. Selected bond lenghths and bond angles are listed in **Table 2**.

2.3. General procedure for synthesis of compounds (1–8)

A solution of thiophene -2-carbonyl chloride (1.06 mmol, 10 mmol) in dry acetone (30 mL) was mixed to a suspension of ammonium thiocyanate (0.78g, 10 mmol) in dry acetone (30 mL) and was heated (60 °C) under reflux for 1 h. The resultant thiophene-2-carbonyl isothiocyanate solution was treated with equimolar quantity of appropriate substituted aromatic primary amine in acetone (Scheme 1) and further refluxed for 2 h at 27 °C [30, 31, 33–35]. The precipitated

ammonium chloride was filtered off and the yellow colour solution was evaporated in vacuum to dryness to obtain crude crystalline product. Yellow crystals of the compound 1 were grown by the slow evaporation of its solution in acetone/dichloromethane (1:1) in one week at 20°C.

2.3.1. N-(2, 4 – dichlorophenyl) - N'- (thiophene-2-carbonyl)-thiocarbamide (1)

Light yellow solid; (2, 4-dichloroaniline, 1.630g, 10 mmol); Yield: 80%, m.p. 175–176°C. FT–IR (KBr, cm⁻¹): 3411, 3117, v (N–H); 3029, v (Ar, C–H); 1667, v (C=O); 1273, v (C=S); 1157, v(NCN); 776,(C–S); 661, v_{as} (C–Cl); 478, v_{s} (C–Cl). ¹H NMR (500 MHz, CDCl₃, 25°C): δ (ppm) 12.54 (s, 1H, –CSNH), 9.10 (s, 1H, –CONH), 8.37 (d, 1H, J = 8.5 Hz, Thiophene-H), 7.76 (dd, 1H, J₁ = 8.5 Hz, J₂ = 3.2 Hz, Thiophene-H), 7.74 (d, 1H, J = 5.1 Hz, Thiophene-H), 7.47-7.30 (m, 2H, Ar-H), 7.29-7.18 (m, 2H, Ar-H). ¹³C NMR (125 MHz CDCl₃, 25°C): δ (ppm) 178.5 (C=S), 161.1 (C=O), 135.7, 134.7, 133.8, 132.5(Thiophene, Cs), 131.1, 129.5, 128.7, 128.6, 127.2, 126.9 (Ar, Cs). Anal. Calcd. for C₁₂H₈N₂OS₂Cl₂ (331.00): C, 43.51; H, 2.43; N, 8.46, Found: C, 43.47; H, 2.39; N, 8.38 %.

2.2.2. N-(4-chloro-3-nitrophenyl) - N'- (thiophene-2-carbonyl)-thiocarbamide (2)

Yellow solid; (4-chloro-3-nitroaniline, 1.731g, 10 mmol); Yield: 91%, m.p. 100–101°C. FT–IR (KBr, cm⁻¹): 3263, 3105, v(N–H); 3072, v(Ar, C–H); 1659, v(C=O); 1556, v_{as}(–NO₂); 1356,v_s(–NO₂); 1272, v(C=S); 1163,v(NCN); 766, v(C–S); 724, v_{as}(C–Cl); 486, v_s(C–Cl). ¹H NMR (500 MHz, CDCl₃, 25°C): δ (ppm) 12.71 (s, 1H, –CSNH), 9.03 (s, 1H, –CONH), 8.51 (d, 1H, J = 7.5 Hz, Thiophene-H), 7.85 (dd, 1H, J₁ = 6.0 Hz, J₂ = 3.5 Hz, Thiophene-H), 7.76 (d, 1H, J = 5.0 Hz, Thiophene-H), 7.70-7.54 (m, 2H, Ar-H), 7.24-7.15 (m, 2H, Ar-H). ¹³C NMR (125 MHz CDCl₃, 25°C): δ (ppm) 182.1 (C=S), 161.5 (C=O), 137.1, 135.1, 134.5, 132.1(Thiophene, Cs), 131.3, 128.8, 128.5, 128.1, 124.4, 120.6 (Ar, Cs). Anal. Calcd. for C₁₂H₈N₃O₃S₂Cl (341.50): C, 42.17; H, 2.36; N, 12.29, Found: C, 42.09; H, 2.33; N, 12.19 %.

2.2.3. N-(4-methoxycarbonyl) phenyl)-N'-(thiophene-2-carbonyl)-thiocarbamide (3)

Light yellow solid; (4-methoxycarbonylphenyl aniline, 1.520g, 10 mmol); Yield: 88%, m.p. 170–171°C. FT–IR (KBr, cm⁻¹): 3296, 3147, v(N–H); 3097, v(Ar, C–H); 1721, v(–COOR); 1698, v(C=O); 1270, v(C=S); 1143, v(NCN); 769,v(C–S). ¹H NMR (500 MHz, CDCl₃, 25°C): δ (ppm) 12.65 (s, 1H, –CSNH), 8.94 (s, 1H, –CONH), 8.08 (d, 1H, J = 8.5 Hz, Thiophene-H), 7.87 (dd, 1H, J₁ = 8.5 Hz, J₂ = 3.2 Hz, Thiophene-H), 7.74 (d, 1H, J = 5.1 Hz, Thiophene-H), 7.24–7.21 (m, 2H, Ar-H), 7.20–7.19(m, 2H, Ar-H), 3.91(s, 3H, –COOCH₃). ¹³C NMR (125 MHz CDCl₃, 25°C): δ (ppm) 177.4 (C=S), 161.1 (C=O), 139.1, 137.1, 134.5, 132.1(Thiophene,

Cs), 131.3, 130.7, 130.2, 128.3, 122.6, 121.4 (Ar, Cs), 58.1 (C, –COOCH₃). Anal. Calcd. for C₁₄H₁₂N₂O₃S₂ (320.38): C, 52.48; H, 3.78; N, 8.74, Found: C, 52.27; H, 3.72; N, 8.68 %.

2.2.4. N-(3-methoxycarbonyl) phenyl)-N'-(thiophene-2-carbonyl)-thiocarbamide (4)

Light yellow solid; (3-methoxycarbonylphenyl aniline, 1.520g, 10 mmol); Yield: 92%, m.p. 95–96°C. FT–IR (KBr, cm⁻¹): 3332, 3140, v(N–H); 3094, v(Ar, C–H); 1709,v(–COOR); 1666, v(C=O); 1263, v(C=S); 1137,v(NCN); 736,v(C–S). ¹H NMR (500 MHz, CDCl₃, 25°C): δ (ppm) 13.27 (s, 1H, –CSNH), 10.01 (s, 1H, –CONH), 8.37 (d, 1H, J = 8.0 Hz, Thiophene-H), 8.04 (dd, 1H, J₁ = 8.0 Hz, J₂ = 3.4 Hz, Thiophene-H), 7.99 (d, 1H, J = 4.1 Hz, Thiophene-H), 7.37–7.34 (m, 2H, Ar-H), 7.33–7.20(m, 2H, Ar-H), 3.94(s, 3H, –COOCH₃). ¹³C NMR (125 MHz CDCl₃, 25°C): δ (ppm) 177.9 (C=S), 166.4 (C=O), 138.4, 136.1, 134.2, 132.3(Thiophene, Cs), 131.4, 130.7, 130.8, 128.4, 127.0, 126.2 (Ar, Cs), 57.8 (C, –COOCH₃). Anal. Calcd. for C₁₄H₁₂N₂O₃S₂ (320.38): C, 52.48; H, 3.78; N, 8.74, Found: C, 52.39; H, 3.76; N, 8.66 %.

2.2.5. N-(2-methoxycarbonyl) phenyl)-N'-(thiophene-2-carbonyl)-thiocarbamide (5)

Light yellow solid; (2-methoxycarbonylphenyl aniline, 1.520g, 10 mmol); Yield: 85%, m.p. 97–98°C. FT–IR (KBr, cm⁻¹): 3332, 3300, v(N–H); 3088,v(Ar, C–H); 1715,v(–COOR); 1690, v(C=O);1262,v(C=S); 1163,v(NCN); 758,v(C–S).¹H NMR (500 MHz, CDCl₃, 25°C): δ (ppm) 11.93 (s, 1H, –CSNH), 9.80 (s, 1H, –CONH), 8.71 (d, 1H, J = 9.0 Hz, Thiophene-H), 8.28 (dd, 1H, J₁ = 8.5 Hz, J₂ = 2.4 Hz, Thiophene-H), 7.99 (d, 1H, J = 4.1 Hz, Thiophene-H), 7.97–7.92 (m, 2H, Ar-H), 7.87–7.86(m, 2H, Ar-H), 3.87 (s, 3H, –COOCH₃). ¹³C NMR (125 MHz CDCl₃, 25°C): δ (ppm) 178.8 (C=S), 160.1 (C=O), 139.9, 138.2, 134.6, 132.1(Thiophene, Cs), 131.1, 130.7, 130.7, 128.4, 127.8, 126.7 (Ar, Cs), 57.6 (C, –COOCH₃). Anal. Calcd. for C₁₄H₁₂N₂O₃S₂ (320.38): C, 52.48; H, 3.78; N, 8.74, Found: C, 52.38; H, 3.75; N, 8.67 %.

2.2.6. N-(4-methoxyphenyl) - N'- (thiophene-2-carbonyl)-thiocarbamide (6)

Yellow solid; (4-methoxyphenyl aniline, 1.231g, 10 mmol); Yield: 78%, m.p. 120–121°C. FT–IR (KBr, cm⁻¹): 3458, 3207, v (N–H); 3086, v (Ar, C–H); 1658, v(C=O); 1285,v(C=S); 1180, v(NCN); 776, v(C–S). ¹H NMR (500 MHz, CDCl₃, 25°C): δ (ppm) 13.27 (s, 1H, –CSNH), 8.97 (s, 1H, –CONH), 8.48 (d, 1H, J = 7.5 Hz, Thiophene-H), 8.05 (dd, 1H, J₁ = 6.5 Hz, J₂ = 2.1 Hz, Thiophene-H), 7.99 (d, 1H, J = 4.0 Hz, Thiophene-H), 7.59–7.57 (m, 2H, Ar-H), 7.33–7.31 (m, 2H, Ar-H), 3.95 (s, 3H, –OCH₃). ¹³C NMR (125 MHz CDCl₃, 25°C): δ (ppm) 178.4 (C=S), 160.0 (C=O), 138.6, 136.2, 134.1, 132.5(Thiophene, Cs), 131.1, 130.9, 128.4, 126.5, 126.2,

122.6 (Ar, Cs), 52.6 (C, –OCH₃). Anal. Calcd. for C₁₃H₁₂N₂O₂S₂ (292.37): C, 53.40; H, 4.14; N, 9.58, Found: C, 53.24; H, 4.09; N, 9.47 %.

2.2.7. N-(2-methoxyphenyl) - N'- (thiophene-2-carbonyl)-thiocarbamide (7)

Yellow solid; (2-methoxyphenyl aniline, 1.231g, 10 mmol); Yield: 75%, m.p. 115–116°C. FT–IR (KBr, cm⁻¹): 3468, 3262, v(N–H); 3105,v(Ar, C–H); 1673, v(C=O); 1270, v(C=S); 1119,v(NCN); 762,v(C–S). ¹H NMR (500 MHz, CDCl₃, 25°C): δ (ppm) 12.40 (s, 1H, –CSNH), 9.03 (s, 1H, –CONH), 7.74 (d, 1H, J = 10.0 Hz, Thiophene-H), 7.65 (dd, 1H, J₁ = 9.5 Hz, J₂ = 4.1 Hz, Thiophene-H), 7.99 (d, 1H, J = 4.0 Hz, Thiophene-H), 7.59–7.57 (m, 2H, Ar-H), 7.33–7.31 (m, 2H, Ar-H), 3.95 (s, 3H, –OCH₃). ¹³C NMR (125 MHz CDCl₃, 25°C): δ (ppm) 178.2 (C=S), 161.3 (C=O), 138.3, 136.1, 135.8, 134.6(Thiophene, Cs), 132.3, 131.0, 130.1, 129.1, 128.6, 125.4 (Ar, Cs), 58.5 (C, –OCH₃). Anal. Calcd. for Calc. for C₁₃H₁₂N₂O₂S₂ (292.73): C, 53.40; H, 4.14; N, 9.58, Found: C, 53.27; H, 4.11; N, 9.51 %

2.2.8. N-(2-nitrophenyl) - N'- (thiophene-2-carbonyl)-thiocarbamide (8)

Dark yellow solid; (2-nitroaniline aniline, 1.381g, 10 mmol); Yield: 91%, m.p. 155–156°C. FT–IR (KBr, cm⁻¹): 3318, 3101, v(N–H); 3005,v(Ar, C–H); 1661,v(C=O); 1564, v_{as}(–NO₂), 1319, v_s(–NO₂); 1264, v(C=S); 1154,v(NCN); 743,v(C–S). ¹H NMR (500 MHz, CDCl₃, 25°C): δ (ppm) 12.88 (s, 1H, –CSNH), 9.01 (s, 1H, –CONH), 8.28 (d, 1H, J = 8.5 Hz, Thiophene-H), 7.78 (dd, 1H, J₁ = 6.0 Hz, J₂ = 3.1 Hz, Thiophene-H), 7.75 (d, 1H, J = 5.5 Hz, Thiophene-H), 7.24–7.21 (m, 2H, Ar-H), 7.20–7.19(m, 2H, Ar-H). ¹³C NMR (125 MHz CDCl₃, 25°C): δ (ppm) 178.1 (C=S), 161.5 (C=O), 145.2, 143.3, 135.5, 135.0(Thiophene, Cs), 131.1, 128.8, 124.6, 123.2, 121.1 (Ar, Cs).Anal. Calcd. For C₁₂H₉N₃O₃S₂ (307.40): C, 46.89; H, 2.95; N, 13.67, Found: C, 46.78; H, 2.92; N, 13.58 %

3. Biological assays

3.1. Cell lines

Seven human cancer cell lines namely, cervical (2008 and C13*), colorectal (HT29 and HCT116) and ovarian carcinoma (IGROV-1, A2780 and A2780/CP) were used. Among these, C13* and A2780/CP are cisplatin (ccDDP)-resistant cells [36, 37]. Cells were grown as monolayers in RPMI 1640 medium containing 10% heat-inactivated fetal bovine serum and 50 μ g/ml gentamycin sulfate. All cell media and serum were purchased from Lonza (Verviers, Belgium). Cultures were equilibrated with humidified 5% CO₂ in air at 38 °C. All studies were

performed in Mycoplasma negative cells, as routinely determined with the MycoAlert Mycoplasma detection kit (Lonza, Walkersville, MD, USA).

3.2 Cytotoxicity screening

In vitro cytotoxicity of compounds used in the present study was determined by MTT assay [38, 39]. The cells were seeded into 96-well plates and cultured overnight .Various concentrations of the test compounds dissolved in DMSO solvents were then added and incubated for 72 h. After incubation, the medium was removed and added fresh culture medium 100 μ l containing 0.5 mg mL⁻¹ MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenytetrazolium bromide; Sigma) and then incubated at 38°C for 4 h. The medium was removed and 100 μ L DMSO solvent was added to dissolve the dark blue crystals. After incubation for 30 min at room temperature, to ensure that all crystals were dissolved, absorbance was measured using an ELISA plate reader at 570 nm with reference wavelength of 650 nm.

CR CR

4. Results and Discussion

4.1 Synthesis and Characterization

Two step synthesis of compounds **1–8** were accomplished by the reaction of thiophene-2carbonyl chloride with ammonium thiocyanate and refluxing the resultant thiophene-2-carbonyl isothiocyanate with appropriate substituted aromatic primary amines (**Scheme 1**). All the compounds were obtained in good yield. The slow evaporation at room temperature of acetone solution of compound (**1**) afforded single crystals suitable for X-ray diffraction.



Scheme 1 Synthetic route to new thiophene-2-carbonyl-thiocarbamides (1 - 8)

4.2. FT-IR study

In the IR spectra of compounds a sharp and a broad band observed at ~3400 cm⁻¹ and ~3140 cm⁻¹ could be assigned to N1–H and N2···H stretching modes, respectively [40, 41]. The appearance of N2–H stretching vibration at a lower wave number is due to the presence of intramolecular hydrogen bonding N2–H···O=C whereas the first band may be attributed to free v(N1–H) [13]. Characteristic C–H stretching vibrations of the aromatic groups appear as medium intensity band at ~3050 cm⁻¹. A strong band at ~1660 cm⁻¹ corresponds to v(C=O) mode

which resembles in frequency to the hydrogen bonded C=O group (N-H···O=C) observed in many similar compounds. A strong and a medium intensity band at ~1265 cm⁻¹ and ~760 cm⁻¹ could be assigned to C=S and C-S stretching modes, respectively [12, 13].

4.3. NMR study

¹H NMR spectra of the compounds (1–8) in CDCl₃ exhibited two singlets at 9.00–10.00 and 12.00–13.31 ppm which could be assigned to free N1–H and hydrogen bonded N2–H, respectively [12, 13]. Aromatic protons appeared as multiplets between 7.20–8.50 ppm. The chemical shift value of free N–H suffers a downfield shift of ~3.0 ppm in DMSO-d₆. Such shifts could be ascribed to the probable hydrogen bonding between the NH and sulfoxide (S=O) moiety [14].

The ¹³C NMR spectra of compounds (**1–8**) depicted all the signals due to magnetically distinct carbons present in them. The peaks related to the carbons in CONH and CSNH groups of the thiocarbamide resonate around 160–170 and 172–182 ppm, respectively [12-14]. The downfield resonance of C=S in comparison to C=O carbon may be related to steric and electronic factors [42].

4.4 Electronic study

Electronic spectra of compounds 1–8 recorded in dichloromethane over the scan range of 200–800 nm show identical trends (Figure S1). A representative UV-Vis spectrum of compound 2 is shown in Figure 1. A weak band centered at ~261 nm and a strong band at ~296 nm in the absorption spectra of compounds can be ascribed to $\pi \to \pi^*$ transitions of thiocarbamide moiety [43].



Fig. 1 UV-Vis spectrum of compound 2 in dichloromethane

4.5 Description of crystal structure

The ORTEP view, unit cell diagram and packing pattern of compound (1) are depicted in Figures **2(a)**, **2(b)** and **2(c)**, respectively. The crystallographic and refinement details are shown in **Table 1**. Selected bond lengths, bond angles and hydrogen bond interaction are listed in **Table 2** and **Table S1**. In molecular structure thiocarbonyl (C=S) and carbonyl (C=O) groups are opposite to each other and are almost coplanar with torsion angles $S(1)-C(6)-N(1)-C(5) = 177.6(3)^{\circ}$ and $N(2)-C(6)-N(1)-C(5) = -3.3(5)^{\circ}$, respectively. The phenyl ring, thiophene and thiocarbamide moiety lie in a plane, which is evidenced by the torsion angle values $N(1)-C(6)-N(2)-C(7) = 173.8(3)^{\circ}$, $C(6)-N(1)-C(5)-C(1) = -169.6(3)^{\circ}$, respectively [14,15]. The molecular structure shows an intramolecular N2-H···O=C hydrogen bond stabilizing the (-C(O)NHC(S)NH-) geometry, forming a pseudo six membered ring (**Table S1**). The C–N, C=S and other bond distances (**Table 2**) exhibit conventional bond parameters similar to other substituted thiocarbamides [44, 45]. Additionally, an offset face to face π - π stacking interaction is also observed in compound (1) between thiophene rings and substituted benzene rings of two molecules [13, 46]. Very weak intermolecular interactions C–H···Cl, C–S···H and C π -C π stabilize the crystal packing and lead to an infinite chain length along the b-axis Figure **2(c)**





Fig. 2 (a) ORTEP diagram of 1 showing the thermal ellipsoids at 50% probability. The intramolecular hydrogen bonds as shown by dashed lines. (b) Unit cell diagram viewed down the b axis for compound 1. Intermolecular face-to-face $\pi - \pi$ stacking interaction is also observed in the compound 1. (c) The packing diagram of compound 1. Weak intermolecular interactions (C-H···Cl, C-S···H and C π -C π) lead to an infinite chain length along the b-axis.

Compound	1
CCDC No	1561945
Empirical formula	$C_{12}H_8Cl_2N_2OS_2$
Formula weight	331.22
Temperature/K	173(2)
Crystal system	orthorhombic
Space group	$P2_{1}2_{1}2_{1}$
a (Å)	3.9537(2)
b (Å)	10.9953(6)
$c(\dot{A})$	30.0239(16)
α, β, γ (°)	90
Volume/Å ³	1305 20(12)
7.	4
$ocalcg/cm^3$	1 686
m/mm ⁻¹	7 402
$\mathbf{F}(000)$	672.0
$C_{\rm rustal size}/{\rm mm}^3$	$0/2.0$ $0/48 \times 0.14 \times 0.08$
Dediction	$0.46 \times 0.14 \times 0.06$ CuVe () = 1.54194)
$\frac{1}{2} \Theta = \frac{1}{2} \Theta = \frac{1}$	$CuKu(\Lambda = 1.34104)$
20 range for data conection/	$0.304 \ 10 \ 142.300$
Index ranges	$-4 \le n \le 4, -12 \le K \le 13, -20 \le 1 \le 30$
Kellections collected	8340 2501 [D]: (0.02(C D : 0.021(C)
Independent reflections	2501 [Rint = 0.0366, Rsigma = 0.0316]
Data/restraints/parameters	2501/0/172
Goodness-of-fit on F	1.029
Final R indexes $[1 \ge 2\sigma(1)]$	$R_1 = 0.0340, wR_2 = 0.0867$
Final R indexes [all data]	$R_1 = 0.0351, wR_2 = 0.0877$
Largest diff. peak/hole / eA ⁻³	0.33/-0.36
Flack parameter	-0.008(13)
$\mathbf{^{a}R} = \mathbf{P} \mathbf{Fo} - \mathbf{Fc} /\mathbf{P} \mathbf{Fo} $	
${}^{D}\mathbf{R}\mathbf{w} = [\mathbf{P}\mathbf{w}(\mathbf{F}\mathbf{o}^{2} - \mathbf{F}\mathbf{c}^{2})_{2}/\mathbf{P}\mathbf{w}(\mathbf{F}\mathbf{o}^{4})]1/2$	2.
X. (

 Table 1. Crystal data and structure refinement for compound 1

Bond Lengths (Å)							
N1-C5 1. N1-C6 1. N2-C6 1. N2-C7 1. O1-C5 1. C6-S1 1.	372(4) 394(4) 346(4) 419(4) 229(4) .660(3)		S2-C1 S2-C4 C10-C11 C12-C12 C8-C11 C10-C12	1.730(3) 1.706(3) 1.388(5) 1.388(4) 1.738(3) 1.733(3)	6		
C4–S2–C1 O1–C5–C1 N1–C6–S1 N2–C6–N1 N2–C7–C12	91.58(16) 122.2(3) 118.3(2) 115.1(3) 118.9(3)	Bond Angles (°)	01–C5–N1 N1–C5–C1 N2–C6–S1 N2–C7–C8 C5–C1–C2	123.4(3) 114.4(3) 126.6(2) 120.3(2) 130.6(3)			
	J. J.						
	V						

Table 2. Selected bond lengths (Å) and bond angles (°) for compound 1
-----------------------------------	--------------------------------------

4.6 In vitro cytotoxicity screening

To evaluate the anti-cancer activity of synthesized substituted thiocarbamides (1-8) and five other (9-13), all the thirteen compounds (1-13) were tested for their in vitro cytotoxicity activities against a panel of seven human cancer cell lines, cervical (2008 and C13*), colorectal (HT29 and HCT116) and ovarian carcinoma (A2780, A2780/CP and IGROV-1) using 5-Fluorouracil (5-FU, a clinically used drug) as a positive control [47–49]. The result in the form of their IC₅₀ values has been presented in Table 3. The comparative cytotoxicity of the compounds is depicted in Figure 3. The structural analysis of compounds 9-13 (N-4-Sulfonamide phenyl-N'-2-thiophenoyl thiourea, N-3-Nitrophenyl-N'-2-thiophenoyl thiourea, N-2-Chloro-4-nitrophenyl-N'-2-thiophenoyl thiourea, N-2-Methoxy-4-nitrophenyl-N'-2-thiophenoyl thiourea and N-4-Chloro-2-nitrophenyl-N'-2-thiophenoyl thiourea) along with their other biological properties have already been published by us [50]. The tested compounds displayed potent inhibitory activity against all the cell lines having IC₅₀ values in different ranges (Table 3). The strongest inhibitory activity was displayed by compounds 1, 11, 12 and 13 against all the cell lines. All the compounds except 5, 9 and 10 displayed stronger inhibitory activity than the standard drug (5-FU) against HT29 cell line. In comparison to the standard drug (5-FU) better inhibitory properties were obtained for compounds 1, 3, 4, 8, 11, 12 and 13 against HCT116 and for compounds 5 and 8 against A2780/CP cancer cell lines, respectively. The present study demonstrates that nature and number of functional groups attached to the phenyl ring of the thiocarbamide moiety exert a decisive influence on the cytotoxicity of this class of compounds. The most promising compounds 1, 11, 12 and 13 contained a nitro and/or chloro electron withdrawing group at ortho and para positions [51, 52] In general, all the above compounds exhibited better inhibitory properties than those reported in our previous papers [12, 13, 30, 31]. Previous studies have shown that the presence of electronegative atom/group at ortho and or/ para position of the aromatic ring increases the lipophilicity of molecules and is responsible for enhanced cytotoxicity in MTT model [53]. Based on the above results, potential anticancer candidates can be considered for structural modification and pharmacological evaluation.

Table 3. IC_{50} Values (μ M) for the compounds (1–13) against seven human cancer cell lines; (2008 and C13*) cervical, (HT29 and HCT116) colorectal and (A2780, A2780/CP and IGROV-1) ovarian carcinoma.

Compounds	Cell lines					R	
	2008	C13*	HT29	HCT116	A2780	A2780/CP	IGROV- 1
1.	7.4±0.3	11.9±0.4	13.4±0.1	11.6±2	21.4±5	19.6±5	15.9±1
2.	11.2±0.4	12.1±0.3	12.9±0.3	13.5±4	19.6±3	23.4±6	17.5±0.4
3.	10.5±0.6	11.8±0.2	11.9±0.6	12.5±0.4	26.2±0.7	24.3±1	20.4±0.9
4.	10.1±0.1	11.2±0.3	11.9±0.3	11.5±0.2	24.6±0.3	27.4±0.2	19.8±10
5.	9.8±0.4	9.75±0.3	22.9±0.5	25.8±0.2	11.4±0.8	10.4±0.5	12.9±1
6.	22.5±0.5	19.6±0.1	15.4±0.3	19.6±0.4	21.4±0.4	22.5±2	23.3±0.6
7.	21.8±0.2	18.9±0.2	14.8±0.6	18.4±0.2	20.6±0.3	21.3±5	21.8±0.7
8.	10.2±0.1	11.1±0.3	10.9±0.2	11.5±0.1	29.3±4	10.6±0.5	21.3±0.7
9.	22.3±0.5	28.6±0.8	21.3±0.6	33.1±0.1	27.4±0.8	35.5±0.9	29.6±0.3
10.	20.7±0.5	22.6±0.6	24.7±0.7	22.8±0.3	27.6±2	31.9±0.6	31.1±0.7
11.	5.4±0.1	11.2±0.2	12.4±0.2	11.9±0.7	15.2±1	14.9±3	13.2±0.4
12.	6.2±0.2	12.3±0.6	13.2±0.2	12.9±0.3	18.5±3	16.4±3	14.8±1
13.	5.1±0.2	10.6±0.5	11.6±0.2	11.2±0.7	15.1±1	14.4±2	11.8±1
5-FU	4.1±0.3	8.5±0.5	15.2±0.1	13.5±0.1	5.5±0.3	12.8±0.5	5.1±0.2



(A)





Fig. 3 Comparative *in vitro* cytotoxicity of compounds **1–13** for a panel of seven human cancer cell lines; (**A**). Cervical (2008 and C13*) (**B**). Colorectal (HT29 and HCT116) (**C**). Ovarian carcinoma (A2780, A2780/CP and IGROV-1).

5. Conclusions

A facile synthesis of a series of N, N'-disubstituted thiocarbamides were performed using the prescribed method in this paper. All these compounds were structurally characterized by using various spectroscopic and single crystal X-ray diffraction techniques. The crystal structure of compound **1** revealed the planar confirmation of thiocarbamide unit which may be due to the formation of intramolecular hydrogen bond N2–H···O=C. An offset face-to-face π – π stacking is also present between aromatic rings of compound **1**.The cytotoxic effects of these compounds were evaluated against seven human cancer cell lines using the standard MTT assay. The IC₅₀ values indicated all of them to be potent anticancer agents against all the cell lines. Most of the tested compounds conferred better inhibitory activity than the standard drug (**5-FU**) against **HT29** and **HCT116** cell lines and are worthy of further structural modification and pharmacological evaluation.

Acknowledgements

The author, SKP is grateful to Banaras Hindu University, Varanasi, India for the financial assistance. I am thankful to Prof. G. Marverti, Department of Biomedical Sciences, Metabolic and neurosciences, University of Modena, 41125 Modena, Italy for cytotoxicity studies. I am also very thankful to Prof. Jerry P. Jasinski, Department of Chemistry, Keene State College, and 229 Main Street, Keene, NH 03435-2001, USA for single crystal X-ray diffraction.

Supporting Information Summary

UV–Vis spectra of compounds (1–8) in dichloromethane Figure S1. Scan copies of ¹HNMR Fig.(S2–S9) and ¹³CNMR Fig.(S10–S17). X-ray crystallographic hydrogen bonding Table S1 of compound (1) have been provided in supporting information. Crystallographic data (excluding structure factors) for the structures in this paper have been deposited with the Cambridge Crystallographic Data Centre, CCDC, 12 Union Road, Cambridge

CB21EZ, UK. Copies of the data can be obtained free of charge on quoting the depository numbers CCDC **1561945** for compound **(1)** (Fax: +44-1223-336-033; Email: deposit@ccdc.cam.ac.uk, http://www.cam.ac.uk)

References

[1] A. Saeed, U. Flörke, M. F. Erben, A review on the chemistry, coordination, structure and biological properties of 1-(acyl/aroyl)-3-(substituted) thioureas, J. Sulfur Chem. 35 (2014) 318–355.

[2] A. A. Aly, E. K. Ahmed, K. M. El-Mokadem, M. El-Amir, F. Hegazy, Update survey on aroyl substituted thioureas and their applications, J. Sulfur Chem. 28 (2007) 73–93.

[3] K. R. Koch, New chemistry with old ligands: *N*-alkyl- and *N*, *N*-dialkyl-*N*_-acyl (aroyl) thioureas in co-ordination, analytical and process chemistry of the platinum group metals, Coord. Chem. Rev. 216–217 (2001) 473–488.

[4] S. Saeed, N. Rashid, P. G. Jones, M. Ali, R. Hussain, Synthesis, characterization and biological evaluation of some thiourea derivatives bearing benzothiazole moiety as potential antimicrobial and anticancer agents, Eur. J. Med. Chem. *45* (2010) 1323–1331.

[5] O. E. Hernández, J. Duque, E. Reguera, Structural features of 1-furoylthioureas 3monosubstituted and 3, 3-disubstituted: coordination to cadmium and analytical applications, J. Sulfur Chem. 32 (2011) 213–222.

[6] N. Gunasekaran, P. Ramesh, M. N. G. Ponnuswamy, R. Karvembu, Monodentate coordination of *N*-[di(phenyl/ethyl)carbamothioyl]benzamide ligands: synthesis, crystal structure and catalytic oxidation property of Cu(I) complexes, Dalton Trans. 40 (2011) 12519–12526.

[7] M. M. Sheeba, M. M. Tamizh, L. J. Farrugia, A. Endo, R. Karvembu, Chiral (η6 p Cymene)ruthenium(II) Complexes Containing Monodentate Acylthiourea Ligands for Efficient Asymmetric Transfer Hydrogenation of Ketones, Organometallics.33 (2014) 540–550.

[8] S. Saeed, R. Hussain, Preparation and characterization of copper sulfide nanoparticles from symmetrical [(Bu)2NC(S)NC(O)C6H3(3,5-NO2)2]2Cu(II) and [(Bu)2NC(S)NC(O)C6H4(4-

NO2)]2Cu(II) complexes by thermolysis, J. Coord.Chem. 67 (2014) 2942–2953.

[9] S. S. Hassan, M. M. Shoukry, R. N. Shallan, R. van Eldik, Synthesis, characterization, speciation and biological studies on metal chelates of 1- benzoyl(1,2,4-triazol-3-yl)thiourea, J. Coord. Chem.70 (2017) 1761–1775.

[10] D. Mahendiran, N. Pravin, N. S. P. Bhuvanesh, R.S. Kumar, V. Viswanathan, D. Velmurugan, A. K. Rahiman, Bis(thiosemicarbazone)copper(I) Complexes as Prospective Therapeutic Agents: Interaction with DNA/BSA Molecules, and In Vitro and In Vivo Anti-Proliferative Activities, ChemistrySelect 3 (2018) 7100–7111.

[11] M. J. McKeage, L. Maharaj, S. J. B. Price, Mechanisms of cytotoxicity and antitumor activity of gold (I) phosphine complexes: the possible role of mitochondria, Coord. Chem. Rev. 232 (2002) 127–135.

[12] S. K. Pandey, D. P. Singh, G. Marverti, R. J. Butcher, S. Pratap, Monodentate Coordination of N, N'-Disubstituted Thiocarbamide Ligands: Syntheses, Structural Analyses, In Vitro Cytotoxicity and DNA Damage Studies of Cu(I) Complexes, ChemistrySelect 3 (2018) 3675–3679.

[13] S. K. Pandey, S. Pratap, G. Gozzi, G. Marverti, R. J. Butcher, Synthesis, molecular structure exploration and *in vitro* cytotoxicity screening of five novel N, N'-disubstituted thiocarbamide derivatives, *Phosphorus, Sulfur, and Silicon Relat. Elem.*193 (2018) 507–514.

[14] M. K. Rauf, S. Zaib, A. Talib, M. Ebihara, A. Badshah, M. Bolte, J. Iqbal, Solution-phase microwave assisted parallel synthesis, biological evaluation and in silico docking studies of N,N'-disubstituted thioureas derived from 3-chlorobenzoic acid, Bioorg. Med. Chem. 24 (2016) 4452–4463.

[15] J. Haribabu, G. R. Subhashree, S. Saranya, K. Gomathi, R. Karvembu, D. Gayathri, Synthesis, crystal structure, and in vitro and in silico molecular docking of novel acyl thiourea derivatives, J. Mol. Struct. 1094 (2015) 281–291.

[16] M. Mahdavi, M. S. Shirazi, R. Taherkhani, M. Saeedi, E. Alipour, F. H. Moghadam, A. Moradi, H. Nadri, S. Emami, L. Firoozpour, A. Shafiee, A. Foroumadi, Synthesis, biological evaluation and docking study of 3-aroyl-1-(4-sulfamoylphenyl)thiourea derivatives as 15-lipoxygenase inhibitors, Eur. J. Med. Chem. 82 (2014) 308–313.

[17] L. Qiao, J. Huang, W. Hu, Y. Zhang, J. Guo, W. Cao, K. Miao, B. Qin, J. Song, Synthesis, characterization, and *in vitro* evaluation and *in silico* molecular docking of thiourea derivatives incorporating 4-(trifluoromethyl)phenyl moiety, J. Mol. Struct. 1139 (2017) 149–159.

[**18**] S. G. Kucukguzel, E. E. Oruc, S. Rollas, F. Sahin, A. Ozbek, Synthesis, characterisation and biological activity of novel 4-thiazolidinones, 1,3,4-oxadiazoles and some related compounds, Eur. J. Med. Chem. 37 (2002) 197–206.

[**19**] V. S. Palekar, A. J. Damle, S.R. Shukla, Synthesis and antibacterial activity of some novel bis-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazoles and bis-4-thiazolidinone derivatives from terephthalic dihydrazide, Eur. J. Med. Chem. 44 (2009) 5112–5116.

[20] F. A. Larik, A. Saeed, P. A. Channar, U. Muqadar, Q. Abbas, M. Hassan, S.Y. Seo, M. Bolte, Design, synthesis, kinetic mechanism and molecular docking studies of novel 1-pentanoyl-3-arylthioureas as inhibitors of mushroom tyrosinase and free radical scavengers, Eur. J. Med. Chem. 141 (2017) 273–281

[21] M. L. Barreca, A. Chimirri, L. D. Luca, A. M. Monforte, P. Monforte, A. Rao, M. Zappala, J Balzarini, E. D. Clercq, C. Pannecouquec, M. Witvr, Discovery of 2,3-Diaryl-1,3-thiazolidin-4-ones as Potent Anti-HIV-1 Agents, Bioorg. Med. Chem. Lett. 11 (2001) 1793–1796.

[22] M. Mushtaque, F. Avecilla, M. S. Khan, Z. B. Hafeez, M. M. A. Rezvi, A. Srivastava, Synthesis, characterization, cytotoxicity, cell cycle analysis of 3-(4-methoxyphenyl)-1-(pyridin-2-ylmethyl)thiourea and quantum chemical analyses, J. Mol. Struct. 1141 (2017) 119–132.

[23] M. M. Habtu, S. A. Bourne, K. R. Koch, R. C. Luckay, Competitive bulk liquid membrane transport and solvent extraction of some transition and post-transition metal ions using acylthiourea ligands as ionophores, New J. Chem. 30 (2006) 1155–1162.

[24] F. Oton, A. Espinosa, A. Tarraga, I. Ratera, K. Wurst, J. Veciana, P. Molina, Mononuclear Ferrocenophane Structural Motifs with Two Thiourea Arms Acting as a Dual Binding Site for Anions and Cations, Inorg. Chem. 48 (2009) 1566–1576.

[25] V. Krishnakumar, C. Ramachandraraja, R.S. Sundararajan, Crystal growth and vibrational spectroscopic studies of the semiorganic non-linear optical crystal-bisthiourea magnesium sulphate, Spectrochim. Acta Part A. 68 (2007) 113–116.

[26] G. Sharma, D. Singh, R. L. Gardas, Effect of Fluorinated Anion on the Physicochemical,

Rheological and Solvatochromic Properties of Protic and Aprotic Ionic Liquids: Experimental and Computational Study, ChemistrySelect 2 (2017) 11653–11658.

[27] S. Khanam, S. K. Pandey, S. K. Rai, D. Verma, J. P. Jasinski, S. Pratap, A. K. Tewari, Synthesis of N, N-Bis-Sulfonylated and N-Alkyl-N-Sulfonylated G1 Dendrimers via Click Reaction: Application of Thiocarbamide based Cu(I) Catalysts, ChemistrySelect 2 (2017) 6370–6374.

[28] C. Puzzarini, Molecular Structure of Thiourea, J. Phys. Chem. A 116 (2012) 4381–4387.

[29] F. Karipcin, M. Atis, B. Sariboga, H. Celik, M. Tas, Structural, spectral, optical and antimicrobial properties of synthesized 1-benzoyl-3-furan-2-ylmethyl-thiourea, J. Mol. Struct. 1048 (2013) 69–77.

[**30**] D. P. Singh, S. Pratap, S. K. Pandey, R. J. Butcher, G. Marverti, N-(naphthyl)-N' - (methoxy carbonyl) thiocarbamide and its Cu (I) complex: synthesis, spectroscopic, X-ray, DFT and in vitro cytotoxicity study, J. Coord. Chem. 68 (2015) 261–276.

[**31**] D. P. Singh, S. Pratap, M. Shukla, Solvent induced geometry transformation of trigonal planar Cu(I) complexes of N-((2/4-methyoxy carbonyl) phenyl)-N'-(ethoxy/methoxy carbonyl) thiocarbamides to square-planar Cu(II) complexes: Synthesis, spectral, single crystal, DFT and in vitro cytotoxic study, Inorg. Chim.Acta. 423 (2014) 386–396.

[32] L.J. Farrugia, WinGX and ORTEP for windows: an update, J. Appl.Cryst. 45 (2012) 849-854.

[33] Z. Weiqun, K. Leng, Y. Zhang, Lu Lude, Structural and spectral studies of N-(4-chloro) benzoyl-N'-2- Tolylthiourea, J. Mol. Struct. 657 (2003) 215–223.

[34] X. Shen, X. Shi, B. Kang, Y. Liu, Y. Tong, L. Gu, Q. Liu, Y. Huang, Preparation and crystal structure of a new Cu(II) complex derived from the desulfurization of N-(p-nitrophenyl) N'- ethoxycarbonyl thiourea, Polyhedron 18 (1999) 33–37.

[**35**] S. K. Pandey, S. Pratap, M. K. Tiwari, G. Marverti, J. P. Jasinski, Experimental and theoretical exploration of molecular structure and anticancer properties of two N, N'-disubstituted thiocarbamide derivatives, J. Mol. Struct. 1175 (2019) 963–970.

[**36**] C. Korch, M. A. Spillman, T.A. Jackson, B. M. Jacobsen, S. K. Murphy, B. A. Lessey, V. C.Jordan, A. P. Bradford, DNA profiling analysis of endometrial and ovarian cell lines reveals misidentification, redundancy and contamination, Gynecol Oncol. 127 (2012) 241–248.

[**37**] A. P. Andrews, A. J. Jones, Characterization of Binding Proteins from Ovarian Carcinoma and Kidney Tubule Cells that are Specific for Cisplatin Modified DNA, Cancer Commun. 3 (1991) 93–102.

[**38**] T. Mosmann, Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays, J. Immunol. Methods. 65 (1983) 55–63.

[**39**] A. A. Stepanenko, V.V. Dmitrenko, Pitfalls of the MTT assay: Direct and off-target effects of inhibitors can result in over/underestimation of cell viability, Gene 574 (2015) 193–203.

[40] M. Atis, F. Karipcin, B. Sarıboga, M. Tas, H, Celik, Structural, antimicrobial and computational characterization of 1-benzoyl-3-(5-chloro-2-hydroxyphenyl) thiourea, Spectrochim. Acta Part A. 98 (2012) 290–301.

[41] O. E. Hernandez, E. O. Sanchez, J.L. H. H. de Cisneros, I. N. Rodriguez, E. Reguera, A Raman and infrared study of 1-furoyl-3-monosubstituted and 3,3-disubstituted thioureas, Spectrochim. Acta Part A. 62 (2005) 964–971.

[42] R. M. Silverstein, X. F. Webster, J. D. Kiemle, Spectrometric Identification of Organic Compounds, Seventh Edition; Wiley: New York. ISBN0-471–39362-2.

[43] A. Saeed, S. Ashraf, J. M. White, D. B. Soria, C. A. Franca, M. F. Erben, Synthesis, X-ray crystal structure, thermal behavior and spectroscopic analysis of 1-(1-naphthoyl)-3-(halophenyl)-thioureas complemented with quantum chemical calculations, Spectrochim. Acta Part A. 150 (2015) 409–418.

[44] A. Saeed, A. Khurshid, J. P. Jasinski, C. G. Pozzi, A. C. Fantoni, M. F. Erben, Competing intramolecular N-H...O=C hydrogen bonds and extended intermolecular network in 1-(4-chlorobenzoyl)-3-(2-methyl-4-oxopentan-2-yl) thiourea analyzed by experimental and theoretical Methods, J. Chem. Phys. 431–432 (2014) 39–46.

[**45**] M. S. M. Yusof, R. H. Jusoh, W. M. Khairul, B. M. Yamin, Synthesis and characterisation a series of N-(3,4-dichlorophenyl)-N'-(2,3 and 4-methylbenzoyl)thiourea derivatives, J. Mol. Struct. 975 (2010) 280–284.

[46] A. Saeed, Z. Ashraf, M. F. Erben, J. Simpson, Vibrational spectra and molecular structure of isomeric 1-(adamantan-1-ylcarbonyl)-3-(dichlorophenyl)thioureas, J. Mol. Struct. 1129 (2017) 283–291.

[47] A. A. Ramos, C. P. Wilsonb, A. R. Collins, Protective effects of Ursolic acid and Luteolin against oxidative DNA damage include enhancement of DNA repair in Caco-2 cells, Mutat. Res. 692 (2010) 6–11.

[48] K. K. Gnanasekaran, D. M. Benbrook, B. Nammalwar, E. Thavathiru, R. A. Bunce, K. D. Berlin, Synthesis and evaluation of second generation Flex-Het scaffolds against the human ovarian cancer A2780 cell line, Eur. J. Med. Chem. 96 (2015) 209–217.

[49] K. M. Khan, F. Naz, M. Taha, A. Khan, S. Perveen, M. I. Choudhary, W. Voelter, Synthesis and in vitro urease inhibitory activity of N,N'-disubstituted Thioureas, Eur. J. Med. Chem. 74 (2014) 314–323.

[50] D. P. Singh, M. Gangwar, D. Kumar, G. Nath, S. Pratap, Synthesis, Spectroscopic Characterization, Crystal structure, Antimicrobial and In Vitro Hemolytic Studies of Some Novel Substituted Thiourea Derivatives, J. Chem. Crystallogr. 43 (2013) 610–621.

[**51**] H. N. Pati, U. Das, J. W. Quail, M. Kawase, H. Sakagami, J. R. Dimmock, Cytotoxic 3,5bis(benzylidene) piperidin-4-ones and N-acyl analogs displaying selective toxicity for malignant cells, Eur. J. Med. Chem. 43 (2008) 1–7.

[52] M. K. Rauf, I. Din, A. Badshah, M. Gielen, M. Ebihara, D. deVos, S. Ahmed, Synthesis, structural characterization and in vitro cytotoxicity and anti-bacterial activity of some copper(I) complexes with N,N'-disubstituted thioureas, J. Inorg. Biochem. 103 (2009) 1135–1144.

[53] S. Saeed, N. Rashid, P. G. Jones, M. Ali, R. Hussain, Synthesis, characterization and biological evaluation of some thiourea derivatives bearing benzothiazole moiety as potential antimicrobial and anticancer agents, Eur. J. Med. Chem. 45 (2010) 1323–1331.

Highlights:

- Single crystal X-ray of compound 1 and various spectroscopic techniques (FT-IR, UV-Vis, ¹H and ¹³C NMR) were used to establish the structure of the compounds.
- ✤ The presence of intramolecular hydrogen bond (N-H…O=C) compels planarity of the molecule and trans orientation of C=O and C=S group.
- The compounds were screened for their *In vitro* cytotoxic activity against seven human cancer cell lines.
- The compounds screened for their cytotoxic activity in seven human cell line carcinomas exhibited promising anticancer activity
- ✤ All the compounds except 5, 9 and 10 displayed stronger inhibitory activity than the standard drug (5-FU) against HT29 cell line.